

Approved for Use through 07/31/2006, OMB 0651-0031

Approved for Use through 07/31/2006, OMB 0651-0031

US Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE GAU:

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a world OMB control number.

If form 1499APTO

Substitute	for form 1449A/PTC	)		Complete if Known		
				Application Number	10/535,345	
INFO	RMATION	DIS	CLOSURE	Filing Date	February 15, 2006	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Graeme Semple	
				Art Unit	To Be Determined	
(Use as many sheets as necessary)				Examiner Name	To Be Determined	
Sheet	1	of	5	Attorney Docket Number	79.US2.PCT	

U.S. PATENT DOCUMENTS								
Examiner	Cito	Document Number	Publication/Issue Date	Neme of Patentee or Applicant of Cited Document	Pages, Columns, Linas, Where Relevar			
Initiels *	Cita No.1	Numbar - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Cited Document	Pessages or Relevant Figures Appear			
		US-						
		US-						
	$\overline{}$	US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						

	Cite No.1	Foreign Patent Document		Name of Petentee or	Pages, Columns, Lines,	
Initials*		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date/Filing Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	AA	WO 2004/032928	04-22-2004	Arena Pharm		
	AB	EP 0529854	03-03-1993	Ortho Pharm		
	BR	WO 2005/016867	02-24-2005	Smithkline		
	BS	WO 2005/016870	02-24-2005	Smithkline		
	BT	WO 2005/077950	08-25-2005	Smithkline		
	BU	WO 2004/033431	04-22-2004	Arena Pharm		
	BV	WO 2005/011677	02-10-2005	Arena Pharm		

Examiner Signature	/Susannah Chung/ (06/19/2008)	Date Considered	

"EXAMINE: Initial if inference consistend, whether or not citation is in conformance with MEPE 603. Crew into through citation it in oil conformance and more consistend. Include copy of this form with east communication to applicant." Algorithm in degination number (optional.) "See Kinds Codes of USPTO Paient Documents as www.upsto.gov or WEPP 901.04. "Enter Office that issued the document, by the two-letter code (WIPD Standard ST3.)." If of Impairs placed to comments, the Indication of the Super or many procede the serial number of the Superior document. When the propriets by mitch as indicated on the document under WIPO Standard ST. 16 if possible. "Applicant is to place a check mark here if English language Transistion is attack."

Inflantations in allached.

The collection of information in required by 37 CFR 197 and 1.98. The information is required to John or retain a bornel's yea public which collection of the collection is desirable to the 2 bear to compete, including application, Confidentially is governed by 38 U.S. C. 129 and 37 CFR 1.41 This collection is destinated to take 2 bear to compete, including application, Confidentially and submitting the completed application from to the USPTO. Time will vavy depending upon the individual case, any comments on the amount of time, you require to complete its from anotice requires the branching of time to be sent to the Chief Information Officer, U.S. Pepters and Trademant Office, U.S. Department of Commerce, P.O. Box 1459, Alexandria, V.A. 22313-1459, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissions or Petaters, P.O. Box 1459, Alexandria, V.A. 22313-1459, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissions for Petaters, P.O. Box 1459, Alexandria, V.A. 22313-1459, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissions for Petaters, P.O. Box 1459, Alexandria, V.A. 22313-1459, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

If you need assistance in complating the form, call 1-800-PTO-9199 and salact option 2.

PFO'S8086(08-03)
Approved for Use hrough 07/31/2008. OMB 0651-0031
U.S. Patents and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless to contrist, availed OMB contrist number

Substitute f	for form 1449B/PTC	)		Complete if Known		
INITOI	THAT TON	DIC	CL OCUEE	Application Number	10/535,345	
			CLOSURE	Filing Dete	February 15, 2006	
STAT	EMENT B	ΥA	PPLICANT	First Nemed Inventor	Graeme Semple	
				Art Unit	To Be Determined	
(Use as many sheets as necessary)				Exeminer Neme	To Be Determined	
Sheel	2	of	5	Attorney Docket Number	79.US2.PCT	

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials *	Cite No.1							
	AC	Le Bas et al., "Radioiodinated analogs of EP 00652218 for the exploration of the tachykinin NK1 receptor by spect," J. Labelled Cpd. Radiopharm. (2001) 44(Suppl 1):S280-S282.						
	AD	Bays et al., "Pharmacotherapy for dyslipidaemia-current therapies and future agents," Expert Opinion on Pharmacotherapy (2003) 4(11):1901-1938.						
	AE	Chang et al., "Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats," Diabetes (1983) 32:830-838.						
	AF	Collier et al., "Radiosynthesis and in-vivo evaluation of the pseudopeptide &-opioid antagonist [135]-ITIPP(V)," J. Labelled Cpd. Radiopharm (1999) 42(Suppl 1):5264-266.						
	AG	Coleman "Diabetes-obesity syndromes in mice," Diabetes (1982) 31(Suppl 1):1-6.						
	AH	Coleman et al., "Fat (fat) and tubby (tub): two autosomal recessive mutations causing obesity syndromes in the mouse," J. Heredity (1990) 81:424-427.						
	AI	Cornhill et al., "Topographic study of sudanophilic lesions in cholesterol-fed minipigs by image analysis," Arteriosclerosis, Thrombosis and Vascular Biology (1985) 5(5):415-426.						
	AJ	Delporte et al., "Pre- and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies," Biochem Journal (2002) 367:677-85.						
	AK	Erikkson et al., "Increased incidence of congenital malformations in the offspring of diabetic rats and their prevention by maternal insulin therapy," Diabetes (1982) 31:1-6.						
	AL	Friedman et al., "Tackling a weighty problem," Cell (1992) 69:217-220.						
	AM	Gerrity et al., "Diabetes-induced accelerated atherosclerosis in swine," Diabetes (2001) 50(7):1654- 1665.						

$\overline{}$			
Examiner Signature	/Susannah Chung/ (06/19/2008)	Date Considered	

"EXAMINEE: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,
'Applicant's unique citation designation number (optional), 'Applicant is to place a check mark here if English language Translation is attacked.
'Applicant's unique citation designation number (optional), 'Applicant is to place a check mark here if English language Translation is attacked.
This collection of Information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by

This collection of information is required by 3° CER 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Conflicterishing by general by 5° US. C. 122 and 3° CER 1.41. This collection is estimated to lake 120 minutes to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer. US 10° All the Complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer. US 10° All the Chief and 10° All the Chi

If you need essistence in completing the form, call 1-800-PTO-9199 end select option 2.

PTO/SB/08b(08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449B/PTO Complete if Known 10/535.345 Application Number INFORMATION DISCLOSURE Filing Dete February 15, 2006 STATEMENT BY APPLICANT First Nemed Inventor Graeme Semple Art Unit To Be Determined (Use as many sheets as necessary) Exeminer Name To Be Determined of 5 Attomey Docket Number 79.US2.PCT Sheet | 3

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	r Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the tem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	AN	Guyton "Effect of niacin on atherosclerotic cardiovascular disease," Am. J. Cardiol. (1998) 82:18U-23U.				
	AO	Koranyi et al., "Glucose transporter levels in spontaneously obese (db/db) insulin-resistant mice," J. Clin Invest (1990) 85:962-967.				
	AP	Lorenzen et al., "Characterization of a G protein-coupled receptor for nicotinic acid," Molecular Pharmacology (2001) 59(2):349-357.				
	AQ	Lorenzen et al., "G protein-coupled receptor for nicotinic acid in mouse macrophages," Biochemical Pharmacology (2002) 64:645-648.				
	AR	Matsuda et al., "Role of adiponectin in preventing vascular stenosis. The missing link of adipovascular axis," J. Biol. Chem. (2002) 277(40):37487-91.				
•	AS	Royo et al., "Effect of gemfibrozil on peripheral atherosclerosis and platelet activation in a pig model of hyperlipidemia," Eur J Clin Invest. (2000) 30(10):843-52.				
	AT	Truett et al., "Rat obesity gene fatty (fa) maps to chromosome 5: evidence for homology with the mouse gene diabetes (db)," Proc. Natl. Acad. Sci. USA (1991) 88(17):7806-7809				
	AU	Zhu et al., "Synthesis and mode of action of (125)1- and (3)H-labeled thieno[2,3-c)pyridine antagonists of cell adhesion molecule expression," J. Org. Chem. (2002) 67:943-948.				
	AV	Goodman and Gilman's Pharmacological Basis of Therapeutics, editors Harmon JG and Limbird LE, Chapter 36, Mahley RW and Bersot TP (2001) pp. 971-1002.				
	*AW	Hudlicky, Oxidations in Organic Chemistry, ACS Monograph 186 (1990).				
	*AX	Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, Tenth Edition (1983).				

Examiner Signature	/Susannah Chung/ (06/19/2008)	Date Considered	]

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (opinous). \*Applicant is unique citation designation. \*Applicant is unique citation. \*Applica

'Applicants' unique clation designation number (optional), "Applicant is to place a check mark here it English language Translation is a statched.
This collection of Information is required by 37 CFR 1.98. The information is required to batian or tential a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preserging, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this bruten, should be sent to the Chief information Officer, U.S. Patent and Tridemark Officer, U.S. Department of Commence, P.O. Box 1450, Alexandria, V.A. 2231-1450. DON'S END TSP.C. The William of the Chief information Officer, U.S. Patent and To Indemarks Officer, U.S. Patent and To AVI 2331-3450.

If you need essistance in completing the form, cell 1-800-PTO-9199 and select option 2.

PTO/SB/08b(08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to re spond to a collection of information unless it contains a valid OMB control number Substitute for form 1449B/PTO Complete if Known Application Number 10/535,345 INFORMATION DISCLOSURE Filing Date February 15, 2006 STATEMENT BY APPLICANT First Named Inventor Graeme Semple Art I Init To Be Determined (Use as many sheets as necessary) Examiner Name To Be Determined Sheet of 5 Attorney Docket Number 79.US2.PCT

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials *	r Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the kem (book, magazine, journal, serial, symposium, catalog, etc.), dale, page(s), volume-issue number(s), publisher, city and/or country where published.							
	*AY	Smith et al., Advanced Organic Chemistry (2001) 5th Edition, Wiley-Interscience.						
	*AZ	Larock, Comprehensive Organic Transformations, A Guide to Functional Group Preparations, 2nd Edition, VCH Publishers, Inc. (1999).						
	*BA	Wuts et al., Protective Groups in Organic Synthesis, 3rd Edition, John Wiley and Sons (1999).						
	*88	Jacques et al., Enantiomers, Racemates and Resolutions (1981) John Wiley and Sons, New York.						
	*BC	Remington, The Science and Practice of Pharmacy (2000) 20th Edition, Lippincott Williams & Wilkins (Editors: Gennaro et al.)						
	*BD	Higuchi et al., "Pro-drugs as novel delivery systems," Vol. 14 of the A.C.S. Symposium Series.						
	*BE	Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press (1987).						
	BF	Shafrir "Diabetes in Animals," <u>Diabetes Mellitus</u> , Rifkin et al., Eds [Elsevier Science Publishing Co., New York, ed. 4, (1990) pp.299-340.]						
	ВG	Horikoshi et al., "Troglitazone (CS-045), a new Antidiabetic Drug," Annu Rep Sankyo Res Lab (1994) 46:1-57.						
	вн	ElAmin et al., "Removal of benzyl-type protecting groups from peptides by catalytic transfer hydrogenation with formic acid," J Org Chem (1979) 44(19):3442-3444.						
	BI	Flechtner-Mors et al., "Effects of acipimox on the lipolysis rate in subcutaneous adipose tissue of obese subjects," Diabetes/Metabolism Research and Reviews (2001) 17:387-390.	Γ					

Signature			Considered				

/Susannah Chung/ (06/19/2008) Date

Examiner

Exhausters intak in indicates consistency, whereing the couplet is a consistency of the c

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SRIGHQR-03
Approved for use through 07/31/2006, OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to rescond by a collection of Information unless to contain a walf OMB control number

	Substitute for form 1449B/PTO				Complete if Known			
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/535,345		
					Filing Date	February 15, 2006		
					First Nemed Inventor	Graeme Semple		
					Art Unit	To Be Determined		
_	(Use as many sheets as necessary)				Exeminer Name	To Be Determined		
₹	Sheet	5	of	5	Attorney Docket Number	79.US2.PCT		

	1	landed are after such as Go CADITAL LETTERS Will after a state (when appropriate) title of	
Examiner nitials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
	ВЈ	Haddach et al., "An efficient method for the N-debenzylation of aromatic heterocycles," Tetrahedron Letters (2002) 43:399-402.	
	вк	van Herk et al., "Pyrazole derivatives as partial agonists for the nicotinic acid receptor," J Med Chem (2003) 46:3945-3951.	
	BL	Holland et al., "Heterocyclic tetrazoles, a new class of lipolysis inhibitors," Journal of Medicinal Chemistry (1967) 10:149-154.	
	ВМ	Krynitsky et al., "2-Ethylhexanonitrile," Organic Syntheses, Coll. (1963) 4:436.	
	BN	Soga et al., "Molecular identification of nicotinic acid receptor," Biochemical and Biophysical Research Communications (2003) 303:364-369.	
	во	Surrey "Malononitrile," Organic Syntheses, Coll. (1955) 3:535.	
	ВР	Tunaru et al., "PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect," Nature Medicine (published online 3 Feb 2003) 1-4.	
	BQ	Wise et al., "Molecular identification of high and low affinity receptors for nicotinic acid," The Journal of Biological Chemistry (2003) 278(11):9869-9874.	

Examiner Signature	/Susannah Chung/ (06/19/2008)	Date Considered	

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. \*Applicants unique retained resignation number (polisions). \*Applicant is unique retained resignation number (polisions). \*Applicant is unique retained resignation number (polisions). \*Applicant surject existing existin

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to the (and by the USPTO to process) an application. Confidentiality is pervented by 58 U.S. C.1.22 and 37 CFR 1.4. This collection is estimated to take 100 minutes to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual consecutive of the control of t

If you need assistance in completing the form, call 1-800-PTO-9199 end select option 2.